Clinical trials: Hormone Refractory
Prostate Cancer
Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00049257
- Testing
- carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
MEN-10755 in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of MEN-10755 in treating patients who have progressive…
- Trial name
- NCT00027781
- Testing
- sabarubicin
- Where
- 10 sites in Belgium, France and 4 more
- Volunteers
- 37 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer
Background: No treatment is known to improve survival for prostate cancer patients who have not been helped by previous treatments with hormones and chemotherapy.
- Trial name
- NCT00450619
- Testing
- Samarium Sm 153 lexidronam pentasodium, Sargramostim, Recombinant vaccinia-TRICOM vaccine
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Neoplasms
An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001
The purpose of this study is to provide access to abiraterone acetate for patients who have completed 12 cycles of abiraterone acetate treatment in Clinical Study COU-AA-001 and continue to receive clinical benefit from this…
- Trial name
- NCT01664728
- Testing
- Abiraterone acetate, Glucocorticoid
- Where
- United Kingdom
- Volunteers
- 54 people
- Sponsor
- Janssen Research & Development, LLC
Prostatic Neoplasms
An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer
The purpose of this study is to assess the effects of intetumumab when given in combination with docetaxel and prednisone to participants with metastatic (spread of cancer cells from one part of the body to another)…
- Trial name
- NCT00537381
- Testing
- Docetaxel, Prednisone, Intetumumab
- Where
- 59 sites in United States, Austria and 8 more
- Volunteers
- 131 people
- Sponsor
- Centocor, Inc.
Dermatomyositis, Polymyositis
Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
The purpose of this research study is to evaluate the effectiveness of the study drug, ACTH Gel in people diagnosed with dermatomyositis a disease that causes muscle weakness and is associated with a rash (DM) or polymyositis…
- Trial name
- NCT01906372
- Testing
- Adrenocorticotropic Hormone Gel
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Rohit Aggarwal, MD
Hormone Refractory Prostate Cancer
PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer
This study will evaluate the safety of PD-1 knockout engineered T cells in treating castration resistant prostate cancer (CRPC). Blood samples will also be collected for research purposes.
- Trial name
- NCT02867345
- Testing
- PD-1 Knockout T Cells, Cyclophosphamide, IL-2
- Where
- China
- Sponsor
- Peking University
Metastatic Breast Cancer
Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer
POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin. Different doses and dosing frequencies will be investigated
- Trial name
- NCT01837095
- Testing
- POL6326
- Where
- 12 sites in United States, Spain
- Volunteers
- 54 people
- Sponsor
- Polyphor Ltd.
Prostate Cancer
Vaccine Treatment for Hormone Refractory Prostate Cancer
This 2-phase study will determine the safety of treating patients with prostate cancer with the genetically engineered HyperAcute-Prostate cancer vaccine.
- Trial name
- NCT00105053
- Testing
- HyperAcute-Prostate Cancer Vaccine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- NewLink Genetics Corporation
Hormone Refractory Prostate Cancer
Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone
This is a parallel, two-arm, open-label, multicenter phase IA/IB study of LBH589 (oral formulation) alone and in combination with docetaxel in patients with progressing hormone refractory prostate cancer.
- Trial name
- NCT00493766
- Testing
- LBH589
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Calcitriol Plus Dexamethasone in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Combining calcitriol with dexamethasone may increase the effectiveness of therapy by making cancer cells more sensitive to dexamethasone.
- Trial name
- NCT00010231
- Testing
- calcitriol, dexamethasone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Pittsburgh
Prostate Cancer
Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00255606
- Testing
- docetaxel, prednisone
- Where
- 19 sites in Finland, Ireland and 1 more
- Volunteers
- 360 people
- Sponsor
- Tampere University
Hormone Refractory Prostate Cancer
A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer
This study proposed the comparison the overall survival, hematological toxicity, pain reduction score,PSA levels, tumor response, quality of life in two arms of HRPC patients from different parts of India.
- Trial name
- HRPC (NCT00525408)
- Testing
- Mycobacterium w., Docetaxel
- Where
- 14 sites in India
- Volunteers
- 134 people
- Sponsor
- Cadila Pharnmaceuticals
Prostate Cancer
A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer
The primary purpose of this study is to determine whether LY2181308 in combination with docetaxel is safe and effective treatment for hormone refractory prostate cancer patients.
- Trial name
- NCT00642018
- Testing
- docetaxel, LY2181308 sodium, Prednisone
- Where
- 17 sites in United States, Germany and 2 more
- Volunteers
- 154 people
- Sponsor
- Eli Lilly and Company
Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
Study CP-MGC018-03 is an open-label, two-part, Phase 2 study. Part 1 of the study will enroll participants with metastatic castration-resistant prostate cancer (mCRPC) previously treated with one prior androgen receptor…
- Conditions
- Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer, Androgen-Insensitive Prostatic Cancer, Androgen-Resistant Prostatic Cancer
- Trial name
- Tamarack (NCT05551117)
- Testing
- vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine
- Where
- 63 sites in United States, Australia and 7 more
- Volunteers
- 192 people
- Sponsor
- MacroGenics
Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer
This phase II trial studies how well giving oxaliplatin and pemetrexed disodium together works in treating patients with refractory hormone-resistant prostate cancer.
- Trial name
- NCT01338792
- Testing
- oxaliplatin, pemetrexed disodium, questionnaire administration
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Southern California
Anemia, Fatigue
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
RATIONALE: Epoetin alfa may stimulate red blood cell production and may help improve cancer-related anemia and fatigue. Steroid therapy with dexamethasone may increase the effectiveness of epoetin alfa.
- Conditions
- Anemia, Fatigue, Prostate Cancer
- Trial name
- NCT00060398
- Testing
- epoetin alfa, dexamethasone
- Where
- 140 sites in United States
- Volunteers
- 282 people
- Sponsor
- Eastern Cooperative Oncology Group
Prostatic Neoplasms
Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)
To test the efficacy of CP-751,871 combined with docetaxel and prednisone in the treatment of prostate cancer that is refractory to hormone therapy
- Trial name
- NCT00313781
- Testing
- CP-751,871, docetaxel, prednisone
- Where
- 18 sites in United States, Canada and 4 more
- Volunteers
- 204 people
- Sponsor
- Pfizer
Metastatic Hormone Refractory Prostate Cancer
Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
The goal of this study is to determine the recommended phase 2 dose of the multi-drug combination of abiraterone, cabozantinib, and nivolumab in conjunction with ongoing androgen deprivation therapy in previously untreated…
- Trial name
- NCT04477512
- Testing
- Cabozantinib, Nivolumab, Abiraterone acetate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Metastatic Prostate Cancer
Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer
The proposed phase 1 clinical trial will investigate the safety and tolerability of 177Lu-CYT-500 in patients with metastatic prostate cancer and determine the optimal antibody mass and dose of 177Lu to be used for further study.
- Trial name
- CYT-500 (NCT00441571)
- Testing
- 177Lu-CYT-500
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cytogen Corporation